Sanger Institute-founded PetMedix is working on antibodies for dogs and cats based on an immune system discovery model that will adapt and extend earlier human health research.

PetMedix, a UK-based veterinary medicine producer co-founded by researchers from Wellcome Trust’s Sanger Institute, has received £8m ($10.6m) in a series A round co-led by fund management unit Parkwalk Advisors.
Parkwalk, a subsidiary of commercialisation firm IP Group, co-led the round alongside venture capital firm Digitalis Ventures.
Founded in 2017, PetMedix develops antibody medications for dogs and cats. Its immune system discovery model will extend earlier research conducted for human health with the hope of uncovering therapies specific for a range of species and veterinary diseases.
PetMedix will use the capital to establish its operations and expand its workforce as it continues to develop its platform with a view to beginning drug discovery and creating a pipeline of candidates.
The business is also looking to start collaboration negotiations with potential domestic and international partners. PetMedix’s co-founders include Allan Bradley, a senior group leader at Wellcome Sanger Institute, and Jolyon Martin, who assisted Bradley in his lab.